| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
|
Medicine details |
|
| Medicine name | evolocumab (Repatha®) |
| Formulation | 140 mg and 420 mg solution for injection |
| Reference number | 2109 |
| Indication | Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated. As an adjunct to correction of other risk factors for the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) by lowering LDL-C levels: in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated |
| Company | Amgen Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/05/2019 |
| NICE guidance | TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |